Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Climb Bio, Inc. is a biotechnology company focused on developing innovative therapeutics for immune-mediated diseases. Its pipeline includes monoclonal antibodies targeting B-cell pathways, such as CD19 and APRIL, to treat conditions like membranous nephropathy, ITP, SLE, and IgA nephropathy. The company leverages licensing, strategic acquisitions, and clinical-stage programs to address high unmet medical needs with targeted, potentially disease-modifying therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.